Drug pricing

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

BMS files legal challenge to HHS' 340B rebate decision

Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.

Market Access

Part Two: Navigating the complexities of global market acces...

The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.

News

Overweight man sitting on a bench looking at the American flag

Biden ramps up Medicare coverage of obesity drugs

Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, but will the plan see the light of day?

News

Trump claims comprehensive victory in US election

It is all over bar the shouting win for the US election, with Donald Trump set to claim the Presidency, potentially with the triple whammy of a Republican majority in the Senate, House of R

News

Pharmas ask appeals court to reconsider IRA lawsuits

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits.

ICER identifies new crop of 'unsupported' drug price rises

BMS files legal challenge to HHS' 340B rebate decision

Part Two: Navigating the complexities of global market acces...

Biden ramps up Medicare coverage of obesity drugs

Trump claims comprehensive victory in US election

Pharmas ask appeals court to reconsider IRA lawsuits

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Drug pricing

Editor's Picks